Kaposi Sarcoma Chemotherapy and Research (KS-CARE)

UNC Lineberger Comprehensive Cancer Center

Status

Active, not recruiting

Conditions

HIV

Kaposi Sarcoma

Treatments

Drug: standard of care chemotherapy

Study type

Observational

Funder types

Other

NIH

Identifiers

NCT06480773

3U54CA254564 (U.S. NIH Grant/Contract)

KS-CARE

Details and patient eligibility

About

This prospective, nonrandomized, open-label, single-arm, cohort study examines the effects of chemotherapy provided under local standard of care in patients with pathologically confirmed HIV-associated Kaposi Sarcoma (HIV-KS). Previous HIV-KS studies demonstrated significant variability in clinical outcomes based on differences in gender or baseline KSHV DNA levels in patients with HIV-KS.

Patients will receive chemotherapy according to local site treatment guidelines and standard of care. Chemotherapy regimen for two treatments that are used locally based on physician's choice namely intravenous (IV) Paclitaxel (PTX) or the combination of Bleomycin and Vincristine (BV). In addition, all histologically proven HIV-KS could be enrolled, irrespective of their prior length of combination anti-retroviral treatment (cART). This enrolment strategy will reflect a more realistic picture of HIV-KS management.

This study result could trigger treatment alteration of HIV-KS. The treatment approaches to HIV-KS can be individualized if clinically relevant subsets and novel prognostic markers are defined. In that case, newer and potentially more expensive agents can be selectively applied to those patients most likely to benefit, especially if prolonged treatment is needed.

Enrollment

127 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participants meeting all the inclusion criteria listed below will be eligible for screening.

Histologically confirmed T1 KS presenting to TBH combined Kaposi Sarcoma clinic with or without visceral disease. no evidence of improvement in human immunodeficiency virus (HIV)-associated Kaposi Sarcoma (HIV-KS) in the 4 weeks immediately prior; and a clinical indication for systemic chemotherapy treatment
Known HIV-1 infection status, as documented by any nationally approved, licensed HIV rapid test and confirmed at any time point prior by the local standard of care assay.
On ART or not on ART.
Age ≥18 years.
Participants able to understand and provide written informed consent in English, Afrikaans, or isiXhosa.

Exclusion criteria

Failure to meet the inclusion criteria listed above.

Specifically, pregnancy and breastfeeding are not exclusion criteria given the observational nature of the study with diagnostic and treatment interventions administered according to local standards of care.
Specifically, the absence of skin lesions is not an exclusion criterion if recorded evidence of
visceral or nodal disease is present in the form of a radiology or endoscopy report.
Participants who have had prior chemotherapy or radiotherapy for human immunodeficiency virus (HIV)-associated Kaposi Sarcoma.
Specifically, patients who have had prior cART will not be excluded.
Participants who are receiving any other investigational agents.